相似文献
1
Built to last: gene therapy for ADA SCID.
Blood. 2021 Oct 14;138(15):1287-1288. doi: 10.1182/blood.2021012300.
2
Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
Curr Gene Ther. 2012 Feb 1;12(1):57-65. doi: 10.2174/156652312799789253.
3
A Promising Option for ADA-SCID Patients.
Am J Med Genet A. 2021 Nov;185(11):3184-3185. doi: 10.1002/ajmg.a.61705.
4
Promising Results with Ex Vivo Lentiviral HSPC Gene Therapy in ADA-SCID.
Am J Med Genet A. 2021 Aug;185(8):2291-2292. doi: 10.1002/ajmg.a.61688.
5
ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
Mol Ther. 2016 Jun;24(6):1013-1014. doi: 10.1038/mt.2016.98.
6
Gene therapy for ADA-SCID, the first marketing approval of an gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.
EMBO Mol Med. 2017 Jun;9(6):737-740. doi: 10.15252/emmm.201707573.
7
Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
Hum Gene Ther Clin Dev. 2016 Jun;27(2):57-61. doi: 10.1089/humc.2016.29010.ind. Epub 2016 Jun 6.
8
Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Hum Gene Ther Clin Dev. 2017 Mar;28(1):17-27. doi: 10.1089/humc.2016.191.
9
EMA greenlights second gene therapy.
Nat Rev Drug Discov. 2016 May 3;15(5):299. doi: 10.1038/nrd.2016.93.
10
Omenn Syndrome can Occur during Enzyme Therapy for Adenosine Deaminase Deficiency.
J Clin Immunol. 2024 Jul 15;44(7):162. doi: 10.1007/s10875-024-01764-z.
引用本文的文献
1
Stimulus-Responsive Nanodelivery and Release Systems for Cancer Gene Therapy: Efficacy Improvement Strategies.
Int J Nanomedicine. 2024 Jul 12;19:7099-7121. doi: 10.2147/IJN.S470637. eCollection 2024.
2
Adenosine Deaminase as a Potential Diagnostic and Prognostic Biomarker for Severe Fever with Thrombocytopenia Syndrome.
ACS Omega. 2024 Feb 23;9(9):11005-11011. doi: 10.1021/acsomega.4c00281. eCollection 2024 Mar 5.
3
Advances in gene therapy for inborn errors of immunity.
Curr Opin Allergy Clin Immunol. 2023 Dec 1;23(6):467-477. doi: 10.1097/ACI.0000000000000952. Epub 2023 Oct 13.
4
Changes in Adenosine Deaminase Activity and Endothelial Dysfunction after Mild Coronavirus Disease-2019.
Int J Mol Sci. 2023 Aug 24;24(17):13140. doi: 10.3390/ijms241713140.
5
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
Viruses. 2023 Mar 7;15(3):698. doi: 10.3390/v15030698.
6
Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis.
Front Immunol. 2022 May 18;13:903461. doi: 10.3389/fimmu.2022.903461. eCollection 2022.
本文引用的文献
1
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
Blood. 2021 Oct 14;138(15):1304-1316. doi: 10.1182/blood.2020010260.
2
Gene Therapies for Primary Immune Deficiencies.
Front Immunol. 2021 Feb 25;12:648951. doi: 10.3389/fimmu.2021.648951. eCollection 2021.
3
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
J Clin Invest. 2017 May 1;127(5):1689-1699. doi: 10.1172/JCI90367. Epub 2017 Mar 27.
4
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.
Blood. 2012 Nov 1;120(18):3635-46. doi: 10.1182/blood-2012-02-400937. Epub 2012 Sep 11.
5
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Sci Transl Med. 2011 Aug 24;3(97):97ra80. doi: 10.1126/scitranslmed.3002716.
6
Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
N Engl J Med. 2009 Jan 29;360(5):447-58. doi: 10.1056/NEJMoa0805817.
7
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
Science. 2002 Jun 28;296(5577):2410-3. doi: 10.1126/science.1070104.
Zotero 插件